Nirsevimab first potential immunisation to protect against RSV in infants - European Pharmaceutical Review

3/3/2022 12:00:00 AM3 years 2 months ago

Nirsevimab has the potential to offer RSV protection for all infants, showing 74.5 percent efficacy in the Melody Phase III trial.

Posted: 3 March 2022 | European Pharmaceutical Review | No comments yet Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in the … [+3252 chars]

full article...